Business · 03/03/1999Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for LumenHance Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for LumenHance, a human drug product, in accordance with the law, following a submission to the Commissioner of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →